Baltaleucel-T is under clinical development by Athenex and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Baltaleucel-T’s likelihood of approval (LoA) and phase transition for Nasopharyngeal Cancer took place on 22 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Baltaleucel-T Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Baltaleucel-T overview

Baltaleucel-T (CMD-003) is under investigation for the treatment of nasopharyngeal cancer. It is administered intravenously. CMD-003 is a potent anticancer therapy comprised of cytotoxic T lymphocytes (CTLs) that recognize and kill cells expressing EBV antigens (LMP1, LMP2, EBNA and BARF1). The drug candidate was under development for EBV-positive lymphoma, extranodal NK/T-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), refractory/relased Hodgkin lymphoma, post transplant lymphoproliferative disease, leiomyosarcoma and T-cell lymphomas.

Athenex overview

Athenex, formerly known as Kinex Pharmaceuticals, is a biopharmaceutical company focused on the discovery, development of autologous and allogeneic CAR-NKT cell therapies to treat cancers. The company’s product pipeline includes KUR-501–GD2, KUR-502–CD19, KUR-503–GPC3 and p53-KRAS and EGFR. Athenex platform includes oncology innovation Platform for research and development, commercial platform for manufacturing and marketing of products and global supply chain which provide APIS to clinical and commercial effort. The company partners with pharmaceutical companies, universities and research institutions for the advancement and commercialization of its products. It has operations with product manufacturing facilities in the US, China, Taiwan and Hong Kong. Athenex is headquartered in Buffalo, New York, the US.

Quick View Baltaleucel-T LOA Data

Report Segments
  • Innovator
Drug Name
  • Baltaleucel-T
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Developers
  • Sponsor Company: Athenex
  • Originator: Center for Cell and Gene Therapy
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.